In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: Plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition

Xenobiotica

Volumn 38, Issue 5, 2008, Pages 496-510

  Mukoyoshi, M ^a   Nishimura, S ^a   Hoshide, S ^a   Umeda, S ^a   Kanou, M ^a   Taniguchi, K ^a   Muroga, H ^a  

^a TEIJIN PHARMA LIMITED   (Japan)

Author keywords

Cytochrome P450 (CYP) enzyme; Cytochrome P450 inhibition; Febuxostat; Plasma protein binding; UDP glucuronosyltransferase (UGT) enzyme

Indexed keywords

BEZAFIBRATE; CAPTOPRIL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; FEBUXOSTAT; GLUCURONOSYLTRANSFERASE; IBUPROFEN; NITRENDIPINE; VERAPAMIL; WARFARIN; XANTHINE OXIDASE INHIBITOR;

ARTICLE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME METABOLISM; HUMAN; HUMAN CELL; HYPERURICEMIA; IN VITRO STUDY; MALE; NORMAL HUMAN; PLASMA PROTEIN BINDING; PROTEIN FAMILY;

BLOOD PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; HUMANS; IBUPROFEN; MALE; MICROSOMES, LIVER; PROTEIN BINDING; THIAZOLES; WARFARIN; XANTHINE OXIDASE;

EID: 42249100324     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250801956350     Document Type: Article

References (30)

1. Becker MA, Schumacher Jr HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. 2005. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine 353:2450-2461.
2. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA. 2004. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527-537.
3. Ciotti M, Chen F, Rubaltelli FF, Owens IS. 1998. Coding defect and a TATA box mutation at the bilirubin UDP-glucuronosyltransferase gene cause Crigler-Najjar type I disease. Biochimica et Biophysica Acta 1407:40-50.
4. Dalén P, Dahl M-L, Eichelbaum M, Bertilsson L, Wilkinson GR. 1999. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 9:697-706.
5. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, et al. 1996. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
6. Fehske KJ, Muller WE, Wollert U. 1981. The location of drug binding sites in human serum albumin. Biochemical Pharmacology 30:687-692.
7. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. 2001. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metabolism Reviews 33:273-297.
8. Grabowski BA, Khosravan R, Wu JT, Lademacher C, Vernillet L. 2005. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Arthritis and Rheumatism 52(9 Suppl.):S103-104.
9. Hirano K, Watanabe Y, Adachi T, Ito Y, Sugiura M. 1985. Drug-binding properties of human α-foetoprotein. Biochemical journal 231:189-191.
10. Horiuchi H, Ota M, Nishimura S, Kaneko H, Kasahara Y, Ohta T, Komoriya K. 2000. Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Science 66:2051-2070.
11. Hoshide S, Nishimura S, Ishii S, Matsuzawa K, Saito N, Tanaka T. 2000. Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in human. Drug Metabolism Reviews 32(Suppl. 2):269.
12. m2 in exon 4, in Japanese subjects. Clinical Pharmacology and Therapeutics 59:647-653.
13. Khosravan R, Erdman K, Vernillet L, Wu JT, Joseph-Ridge N, Umeda S, Mulford D. 2005a. Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects. Clinical Pharmacology and Therapeutics 77:43.
14. Khosravan R, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. 2005c. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. Arthritis and Rheumatism 52(Suppl. 9):S102-S103.
15. Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L. 2006. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. Journal of Clinical Pharmacology 46:855-866.
16. Khosravan R, Wu JT, Lademacher C, Grabowski BA, Vernillet L. 2005b. Effect of febuxostat on pharmacokinetics and pharmacodynamics of warfarin. Journal of Clinical Pharmacology 45:1084.
17. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. 1999. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide, and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9:71-80.
18. Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, Nakachi T, Yamanaka H, Kamatani N. 2004. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides, Nucleotides, Nucleic Acids 23:1119-1122.
19. Koyama E, Sohn DR, Shin SG, Chiba K, Shin JG, Kim YH, Echizen H, Ishizaki T. 1994. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. Journal of Pharmacology and Experimental Therapeutics 271:860-867.
20. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. 1997. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
21. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. 2005. Pharmacokinetics and pharmacodynamics of Febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. American Journal of Therapeutics 12:22-34.
22. McGowan FX, Reiter MJ, Pritchett ELC, Shand DG. 1983. Verapamil plasma binding: Relationship to α1-acid glycoprotein and drug efficacy. Clinical Pharmacology and Therapeutics 33:485-490.
23. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. 2003. An extremely potent inhibitor of xanthine oxidoreductase. Journal of Biological Chemistry 278:1848-1855.
24. Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, Komoriya K. 1993. Hypouricemic effect of the novel xanthine oxidase inhibitor, febuxostat, in rodents. European Journal of Pharmacology 241:183-188.
25. Sjöholm I, Ekman B, Kober A, Ljungstedt-Påhlman I, Seiving B, Sjödin T. 1979. Binding of drug to human serum albumin: XI. Molecular Pharmacology 16:767-777.
26. Sudlow G, Birkett DJ, Wade DN. 1976. Further characterization of specific drug binding sites on human serum albumin. Molecular Pharmacology 12:1056-1061.
27. 359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8:365-373.
28. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA. 2005. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Science 76:1835-1847.
29. Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual Review of Pharmacology and Toxicology 40:581-616.
30. Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL. 1979. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clinical Pharmacology and Therapeutics 26:584-591.